Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Vaxcyte will present topline results from the pivotal OPUS-1 Phase 3 trial of its VAX-31 pneumococcal vaccine candidate on October 5. The event creates a binary clinical readout for the company’s lead late-stage program, with safety, tolerability and immunogenicity central to the update.
Vaxcyte said it will host a webcast and conference call on October 5 at 8:00 a.m. ET to present topline data from OPUS-1, a pivotal adult Phase 3 trial of VAX-31. The study is evaluating the 31-valent pneumococcal conjugate vaccine candidate for safety, tolerability and immunogenicity in the prevention of invasive pneumococcal disease and pneumococcal pneumonia.
The announcement schedules the readout rather than reporting the trial results themselves. OPUS-1 is an adult pivotal study, making the presentation an important next data point for Vaxcyte’s clinical-stage vaccine platform and its lead candidate.
The results will touch Vaxcyte’s development program directly: the safety and tolerability findings will address the candidate’s clinical profile, while immunogenicity will provide the key evidence on its vaccine response. The company’s stated target is protection against invasive pneumococcal disease and pneumococcal pneumonia.
No topline findings were included in the announcement. The October 5 presentation should establish the reported safety profile and immunogenicity results, along with the company’s next stated development steps.
Vaxcyte will present topline OPUS-1 Phase 3 results for its 31-valent VAX-31 vaccine on October 5.
The next trading decision turns on the safety and immunogenicity profile Vaxcyte reports for its pivotal adult study, not on the scheduling announcement itself. The October 5 readout is the concrete catalyst; without the results, the clinical and commercial implications remain unresolved.
The readout could show safety, tolerability or immunogenicity results that fail to support the VAX-31 development plan, or the presentation could leave key efficacy and regulatory questions unresolved.
CoverageSource: GlobeNewswire · Published here SUN, OCT 4 · 5:00 PM ET · 2 reports · 1 publisher in this record · latest listed: GlobeNewswire · MON, OCT 5 · 4:37 PM ETHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
A favorable Phase 3 safety and immunogenicity readout would provide pivotal clinical evidence for VAX-31, Vaxcyte’s 31-valent pneumococcal vaccine candidate.
The announcement contains no trial results, so the bear case is that OPUS-1 produces an unfavorable or insufficiently differentiated safety or immunogenicity profile on October 5.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →